Miller Koop Mandy, Ozinga Sarah J, Rosenfeldt Anson B, Alberts Jay L
Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, United States.
IBRO Rep. 2018 Jun 21;5:10-16. doi: 10.1016/j.ibror.2018.06.002. eCollection 2018 Dec.
Gait and balance impairments associated with Parkinson's disease (PD) are often refractory to traditional treatments. Objective, quantitative analysis of gait patterns is crucial in successful management of these symptoms. This project aimed to 1) determine if biomechanical metrics from a mobile device inertial measurement unit were sensitive enough to characterize the effects of anti-parkinsonian medication during the Timed Up and Go (TUG) Test, and 2) develop the Cleveland Clinic Mobility and Balance application (CC-MB) to provide clinicians with objective report following completion of the TUG. The CC-MB captured 3-dimensional acceleration and rotational data from people with PD (pwPD) to characterize center of mass movement while performing the TUG. Trials were segmented into four components: Sit-to-Walk, Gait, Turning, and Stand-to-Sit. Thirty pwPD were tested On and Off (12 h) anti-PD medication. Significant improvements (p < 0.05) between On versus Off conditions included: reduction in MDS-UPDRS III motor scores (10.7%), faster trial times (9.3%), more dynamic walking as evident by increased normalized jerk scores (vertical: 17.3%, medial-lateral: 12.3%), shorter turn durations (10.4%), and faster turn velocities (8%). Measures in Sit-to-Walk and Stand-to-Sit did not show significant changes. Trial time and turn velocity showed excellent test-retest reliability (ICC range: 0.83-0.96) across both medication states. A mobile device platform provided quantitative measures of gait and turning during the TUG that detected significant improvements from anti-parkinsonian medications. This platform is a low-cost, easy-to-use tool that can provide objective reports immediately following the clinical assessments, making it ideal for use in and outside the clinical setting.
与帕金森病(PD)相关的步态和平衡障碍通常对传统治疗方法无效。对步态模式进行客观、定量分析对于成功管理这些症状至关重要。本项目旨在:1)确定来自移动设备惯性测量单元的生物力学指标是否足够敏感,以表征在定时起立行走(TUG)测试期间抗帕金森药物的效果;2)开发克利夫兰诊所移动性和平衡应用程序(CC-MB),以便在TUG测试完成后为临床医生提供客观报告。CC-MB从帕金森病患者(pwPD)中获取三维加速度和旋转数据,以表征执行TUG时的质心运动。试验分为四个部分:从坐到走、步态、转弯和从站到坐。对30名pwPD在服用和停用(12小时)抗PD药物的情况下进行测试。服用与停用药物状态之间的显著改善(p<0.05)包括:MDS-UPDRS III运动评分降低(10.7%)、试验时间加快(9.3%)、归一化急动评分增加表明行走更具动态性(垂直方向:17.3%,内侧-外侧方向:12.3%)、转弯持续时间缩短(10.4%)以及转弯速度加快(8%)。从坐到走和从站到坐的测量结果未显示出显著变化。试验时间和转弯速度在两种药物状态下均显示出出色的重测信度(ICC范围:0.83 - 0.96)。移动设备平台在TUG测试期间提供了步态和转弯的定量测量,检测到抗帕金森药物带来的显著改善。该平台是一种低成本、易于使用的工具,可在临床评估后立即提供客观报告,非常适合在临床环境内外使用。